Investigating the role of eIF4B in diffuse large B-cell lymphoma
Official title: Molecular Characterization of elF4B
Funded at VA Veterans Administration Hospital · NIH-10950307 · Data updated 2026-11-12
This study is looking at a type of cancer called diffuse large B-cell lymphoma (DLBCL) to find new ways to help patients, especially those whose cancer hasn't responded to treatment, by exploring how certain proteins and fat processing in the body might lead to better therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Veterans Administration Hospital NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | October 1, 2022 |
| Project end | September 30, 2026 |
| Funding year | 2025 |
| NIH project number | 5I01BX005789-03 |
| Project ID | NIH-10950307 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with diffuse large B-cell lymphoma, particularly those who have not responded to standard treatments.
✕Less likely to help
Patients with other types of lymphoma or those who are not diagnosed with diffuse large B-cell lymphoma may not benefit from this research.
What this research studies
This research focuses on diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma. It aims to identify novel molecular targets that could improve treatment outcomes for patients, particularly those who experience relapsed or refractory cases. The study will explore the role of eIF4B, a key component of the protein translational machinery, and its relationship with fatty acid metabolism in DLBCL. By understanding these molecular mechanisms, the research seeks to uncover new therapeutic strategies that could be more effective for patients with this type of cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates for patients with diffuse large B-cell lymphoma.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in lymphoma, suggesting that this approach could yield significant insights and potential breakthroughs.
Where this research is happening
-
VA Veterans Administration Hospital
Richmond, United States Active
Researchers
- Principal investigator: Gartenhaus, Ronald B — VA Veterans Administration Hospital
- Study coordinator: Gartenhaus, Ronald B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.